FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the…
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023Drug Master File (DMF) accepted to support future FDA…